DePuy Synthes receives FDA 510(k) clearance of robotic-assisted UKA platform
Click Here to Manage Email Alerts
Key takeaways:
- DePuy Synthes announced FDA clearance of the Velys robotic-assisted unicompartmental knee arthroplasty system.
- The platform is designed to improve implant placement without the use of CT.
DePuy Synthes announced it received FDA 510(k) clearance for the Velys robotic-assisted unicompartmental knee arthroplasty platform, according to a press release.
The Velys UKA platform is designed with robotic guidance to assist in implant positioning without the need for CT scans. The platform previously received FDA clearance for total knee arthroplasty and is now cleared for use in both medial and lateral UKA, according to the release.
“We are committed to continually improving and expanding the capabilities and user experience of our Velys-enabling technology portfolio,” Aldo Denti, group chair of DePuy Synthes, said in the release. “We are excited to add a robotic-assisted offering with our clinically proven implant for UKA which we believe will address some of the key unmet needs in the partial knee replacement segment, including accuracy and simplicity, that other systems on the market do not fully address. Data and analytics will continue to serve as the backbone of our platform, which reveals real-time, actionable insights for surgeons to empower patient-specific operative decisions with the goal to improve outcomes and deliver personalization at scale.”
Read more about
Click Here to Manage Email Alerts